HR Execs on the Move

Medical Laboratory Diagnostics

www.kellysearch.com

 
Find local doctors and healthcare providers near you. See their ratings, reviews, contact info, address, profile, and more.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Anders Hasager
Director - Global Sales and Marketing Profile

Similar Companies

AandA Phamachem

A&A Phamachem Inc. is a Nepean, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Stratus Medical

Advancing RF Technology for the treatment of chronic pain. Nimbus provides a large volume lesion that is cost effective and easy to use.

PharMEDium Healthcare Corporation

PharMEDium is an organization that has established an outstanding reputation for quality and customer service in the healthcare marketplace. Credit for this goes to everyone in the organization. We hope you, too, will find satisfaction and take pride in

Slayback Pharma

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.

Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).